Accessibility Menu
Inhibrx Biosciences logo

Inhibrx Biosciences

(NASDAQ) INBX

Current Price$87.94
Market Cap$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+528%
5 YearN/A
1 Year+270%
1 Month-7%
Inhibrx Biosciences last closing stock price
MetricPriceDate
Last closeUSD 87.392026-07-17
Inhibrx Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.04%USD 93.012026-07-10
1 month-7.23%USD 94.202026-06-17
3 month-0.95%USD 88.232026-04-17
Year to date+10.62%USD 79.002025-12-31
1 year+269.98%USD 23.622025-07-17
Since inception+527.8%USD 13.922024-05-29

Inhibrx Biosciences Financials at a Glance

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.30M

Net Income (TTM)

-$130.19M

EPS (TTM)

-$8.39

P/E Ratio

-10.42

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$87.94

Volume

7,290

Open

$87.99

Previous Close

$87.94

Daily Range

$87.29 - $91.23

52-Week Range

$20.55 - $155.29

Estimated Earnings Date

Aug 12, 2026

INBX News

Foolcom-Featured.png

Inhibrx Biosciences Beats Earnings

Motley Fool Markets TeamAug 13, 2025

INBX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inhibrx Biosciences

Inhibrx develops new medicines for people with serious diseases. Its main drugs aim to help cancer patients who have few treatment options. The company focuses on therapies that target specific disease processes in the body.

What’s in the Medicine Cabinet?

  • Ozekibart (INBRX-109): Drug in clinical trials for rare bone cancer and other solid tumors; 100% of 2025 revenue from licensing.
  • INBRX-106: Drug in trials for several advanced cancers, including lung and skin cancer; no direct revenue yet.
  • Licensing Agreements: Income from licensing technology to partners like Scithera and Regeneron; 100% of 2025 revenue.
  • Preclinical Pipeline: Early-stage research on new cancer therapies; no revenue contribution yet.

Growth Spurts and Strategic Moves

  • Advanced ozekibart and INBRX-106 into Phase 2 clinical trials in 2025.
  • Completed a key trial for ozekibart in chondrosarcoma in 2025.
  • Launched new licensing deals with Scithera (2025) and Regeneron (2024).
  • Expanded clinical trial programs to include more cancer types in 2025.
  • Secured a 43,000 sq. ft. facility in La Jolla, California, with lease through 2028.

Why Inhibrx Stands Out (Without the Lab Coat)

The company uses modular protein engineering to design targeted cancer drugs. It holds a broad patent portfolio, supporting its research and licensing strategy. Inhibrx focuses on rare and hard-to-treat cancers, aiming for regulatory advantages.

Five Things You Need to Know

  • Revenue was $1.3 million in 2025, up 550% from 2024, all from licensing.
  • R&D expense was $113.0 million in 2025, down 45% from 2024.
  • Net loss was $140.1 million in 2025, after a one-time gain in 2024.
  • Cash and equivalents were $124.2 million at December 31, 2025.
  • Debt was $100.6 million at year-end 2025, with $75 million more drawn in March 2026.

Bottom Line

Inhibrx is evolving as a clinical-stage biotech focused on licensing and cancer drug development. The company faces ongoing losses but continues to advance its pipeline and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

110

CEO

Mark Paul Lappe

Website

www.inhibrx.com

Headquarters

La Jolla, CA 92037, US

INBX Financials

Key Financial Metrics (TTM)

Gross Margin

-80.38%

Operating Margin

-9465.46%

Net Income Margin

-10014.23%

Return on Equity

-563.89%

Return on Capital

-117.41%

Return on Assets

-70.77%

Earnings Yield

-9.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.67M

Volume

7.29K

Avg. Volume

470.93K

Financials (TTM)

Gross Profit

-$1.05M

Operating Income

-$123.05M

EBITDA

-$116.10M

Operating Cash Flow

-$131.93M

Capital Expenditure

-$10.00K

Free Cash Flow

-$131.94M

Cash & ST Invst.

$161.66M

Total Debt

$5.90M

Inhibrx Biosciences Performance Analysis

Inhibrx Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,192,000N/A
20232023-12-31USD 1,800,000-17.9%
20242024-12-31USD 200,000-88.9%
20252025-12-31USD 1,300,000550.0%
Inhibrx Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31N/A
Inhibrx Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.03N/A
20232023-12-31USD -16.6766.2%
20242024-12-31USD 116.58N/A
20252025-12-31USD -9.04N/A
Inhibrx Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.9%
Q32025-09-30-23.2%
Q42025-12-317.5%
Q12026-03-31-1.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$537.00K

+20.4%

Gross Margin

0.00%

N/A

Market Cap

$1.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.76M

N/A

Employees

109

N/A

Net Income

-$33.44M

+22.8%

EBITDA

-$29.40M

+26.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$161.66M

-25.3%

Total Debt

$5.90M

-94.5%

Accounts Receivable

$186.00K

-13.1%

Inventory

$0.00

N/A

Long Term Debt

$3.50M

-96.7%

Short Term Debt

$2.41M

+22.0%

Return on Assets

-70.77%

N/A

Return on Invested Capital

-78.15%

N/A

Free Cash Flow

-$38.03M

-5.9%

Operating Cash Flow

-$38.03M

-5.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMTXImmatics N.V.
$9.59+2.02%
NKTRNektar Therapeutics
$68.26+1.80%
ORICORIC Pharmaceuticals, Inc.
$10.73+0.00%
AMLXAmylyx Pharmaceuticals, Inc.
$17.75+4.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%

Questions About INBX

What is the current price of Inhibrx Biosciences?

Inhibrx Biosciences is trading at $87.94 per share.

What is the 52-week range for Inhibrx Biosciences?

Over the past 52 weeks, Inhibrx Biosciences has traded between $20.55 and $155.29.

How much debt does Inhibrx Biosciences have?

As of the most recent reporting period, Inhibrx Biosciences reported total debt of $180.90M.

How much cash does Inhibrx Biosciences have on hand?

Inhibrx Biosciences reported $161.66M in cash and cash equivalents in its most recent financial results.

What is Inhibrx Biosciences’s dividend yield?

Inhibrx Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services